ClinicalTrials.gg
RecruitingNCT06924151AMETHYSTUpdated Sep 4, 2026

Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients

An interventional study of surgical aortic valve replacement and Transcatheter aortic valve replacement in Aortic Stenosis, sponsored by Osaka University. Recruiting at 37 sites in Japan. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Osaka University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Aortic Valve Stenosis with a site in Japan — 4 open to participants now, 7 under way, none of them phase 3. Aortic Valve Stenosis · Japan.

Planned enrollment
4th of 15
450 · median 64
Started
2025
with 1 other
No phase
13 of 19
2 open now
Registered
18th of 19
by date

Among the 19 studies in Aortic Valve Stenosis with a site in Japan, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, and was the 18th registered.

Aortic Valve Stenosis

1,027 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

4 of the 19 studies in Aortic Valve Stenosis with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Aortic Valve Stenosis with a site in Japan, or all of them as a file.
02

Study summary

To establish the safety and effectiveness of surgical aortic valve replacement (SAVR) in patients with isolated severe, calcific aortic stenosis who are at low surgical risk.

Read the detailed description

This study is the Prospective, Randomized, Controlled, Multi-center Study of Isolated SAVR in Low Risk AS Patients (The AMETHYST trial). Patients will be randomized 1:1 to receive either SAVR or transcatheter heart valve replacement (TAVR) with a commercially available surgical and transcatheter bioprosthetic valves. The aim of this study was to assess the non-inferiority of SAVR compared with TAVR for the combined endpoints of death from any cause, stroke and rehospitalization (hospitalization related to biological valves or procedures or heart failure) at 1 year postoperatively. Patients will be seen for follow-up visits at discharge, 30 days, and annually through 10 years.

03

Conditions studied

  • Aortic Stenosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All study participants must meet the following inclusion criteria 1. Severe, calcific aortic stenosis with the following criteria:

    • Jet velocity ≥4.0 m/s or mean gradient ≥ 40 mmHg OR
    • AVA ≤1.0 cm2 or AVA index ≤ 0.6 cm2/m2 Note: Qualifying TTE must be within 90 days prior to randomization

    AND 2. class ≥ II OR Exercisee test that demonstrates a limited exercise capacity, abnormal blood pressure response, or arrhythmia OR Asymptomatic patients with \<50%

  2. The Heart Team agrees that the surgical mortality risk is less than 4% according to STS-PROM. The Heart Team's assessment should include evaluation of overall clinical status and comorbidities that may not be adequately captured by risk calculators such as STS-PROM, in addition to the risk score itself.
  3. The patient has been informed of the nature of the study, agrees to its provisions and has provided written as approved by certified review board.

Exclusion criteria

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are present:

  1. History of cardiovascular surgery or thoracotomy
  2. Pre-existing other valvular disease, coronary artery disease or aortic disease required intervention Note: interventions for arrhythmia or root enlargement are not considered exclusionary.
  3. Heart Team assessment that chest abnormalities or significant frailty would prevent safe SAVR.
  4. Native aortic annulus size unsuitable for sizes the currently approved and marketed SAVR or TAVR based on preoperative 3D-CT image analysis.
  5. Iliofemoral vessel characteristics that whould preclude safe insertion of the introducer sheath.
  6. Evidence of an acute myocardial infarction or PCI ≤ 30 days before randomization
  7. Aortic valve is unicuspid
  8. Severe aortic regurgitation (>3+)
  9. Severe mitral regurgitation (>3+) or ≥ moderate stenosis
  10. Severe tricuspid regurgitation (>3+) or ≥ moderate stenosis
  11. Pre-existing mechanical or bioprosthetic valve in any position.
  12. Complex coronary artery disease:

    1. Heart Team assessment that CABG is recommended at the time of SAVR
    2. Heart Team assessment that optimal revascularization cannot be performed
  13. Symptomatic carotid or vertebral artery disease or treatment of carotid stenosis within 30 days of randomization
  14. Leukopenia (WBC \< 3000 cell/mL), Thrombocytopenia (Plt \< 50,000 cell/mL), history of bleeding diathesis or coagulopathy.
  15. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of randomization
  16. Hypertrophic cardiomyopathy with obstruction (HOCM)
  17. Ventricular dysfunction with \< 30%
  18. Cardiac imaging (echo, CT, and/or MRI) evidence of intracardiac mass, thrombus or vegetation
  19. Inability to tolerate or condition precluding treatment with antithrombotic/anticoagulation therapy during or after the valve implant procedure
  20. Stroke or (TIA) within 90 days of randomization
  21. Renal insufficiency ( \< 30 ml/min per the formula) and/or renal replacement therapy
  22. Active bacterial endocarditis within 180 days of randomization
  23. Severe lung disease ( \< 50% predicted) or currently on home oxygen
  24. Severe pulmonary hypertension (e.g., PA systolic pressure ≥ 2/3 systemic pressure)
  25. History of cirrhosis or active liver disease
  26. Significant abdominal or thoracic aortic disease (such as porcelain aorta, aneurysm, severe calcification, aortic coarctation, etc.) that would preclude cannulation and aortotomy for SAVR or safe passage of the delivery system for TAVR.
  27. Patient refuses blood products.
  28. > 50 kg/m2
  29. Estimated \< 24 months.
  30. Absolute or allergy to iodinated contrast that cannot be adequately treated with pre-medication.
  31. Immobility or significant cognitive impairment that would prevent completion of study procedure.
  32. Currently participating in an drug or another device study.
  33. Unsuitable as candidates by the principal investigator or a research associate for other reasons
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Surgical aortic valve replacement

    Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference

    Procedure: surgical aortic valve replacement

  • Active comparator
    Transcatheter aortic valve replacement

    Transcatheter aortic valve replacement (TAVR) using the device available in Japan in facilities approved to perform TAVR.

    Procedure: Transcatheter aortic valve replacement

Interventions

  • Proceduresurgical aortic valve replacement

    SAVR

  • ProcedureTranscatheter aortic valve replacement

    TAVR

06

What researchers measure

Primary outcomes

  1. Composite endpoint of all-cause mortality, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure)

    Time frame: at 1 year post procedure

Secondary outcomes

  1. the rate of all-cause mortality or disabling stroke

    Time frame: at one year

  2. the rate of all-cause mortality

    Time frame: at one year

  3. the rate of all stroke

    Time frame: at one year

  4. the rate of disabling stroke

    Time frame: at one year

  5. the rate of rehospitalization (valve-related or procedure-related and including heart failure)

    Time frame: at one year

  6. the rate of new bundle branch block or new pacemaker implantation

    Time frame: at one year

  7. the rate of new onset of atrial fibrillation

    Time frame: at 30 days

  8. the rate of life-threatening bleeding

    Time frame: at one year

  9. the rate of occurrence of perivalvular regurgitation ≥ mild by echocardiography

    Time frame: at one year

  10. Quality of life as assessed by KCCQ

    Time frame: at one year

  11. Quality of life as assessed by EQ-5D-5L

    Time frame: at one year

  12. the rate of prosthetic valve endocarditis

    Time frame: at one year

  13. the rate of prosthetic valve thrombosis

    Time frame: at one year

  14. the rate of valve-related dysfunction requiring repeat procedure

    Time frame: at one year

Other outcomes

  1. All cause mortality

    Time frame: at 30 days

  2. The rate of all stroke (disabling and nondisabling)

    Time frame: at 30 days

  3. The rate of Rehospitalization (valve-related or procedure-related and including heart failure)

    Time frame: at 30 days

  4. All cause mortality or all stroke

    Time frame: at one year

  5. All cause mortality or disabling stroke

    Time frame: at 30 days

  6. The rate of vascular complications (major)

    Time frame: at 30 days and one year

  7. The rate of Bleeding complications (life threatening, disabling or major)

    Time frame: at 30 days

  8. The rate of myocardial infarction

    Time frame: at 30 days and one year

  9. The rate of acute kidney injury

    Time frame: at 30 days

  10. the rate of new bundle branch block or new pacemaker implantation

    Time frame: at 30 days

  11. the rate of occurrence of perivalvular regurgitation ≥ mild by echocardiography

    Time frame: at 30 days

  12. The rate of coronary obstruction requiring intervention

    Time frame: at 30 days and one year

  13. New York Heart Association class

    NYHA Classification criteria: Class I: Subjects with cardiac disease but without resulting limitations of physical activity Class II: Subjects with cardiac disease resulting in slight limitation of physical activity Class III: Subjects with cardiac disease resulting in marked limitation of physical activity Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort

    Time frame: at 30 days and one year

  14. Six-minute walk test

    Time frame: at 30 days and one year

  15. The length of postoperative ICU stay

    Time frame: up to one year

  16. Discharge location

    * Home \[including return to pre-admission facilities (excluding hospitals)\] * Other hospital \[excluding rehabilitation hospital\] * Rehabilitation hospital * Death * Other

    Time frame: up to one year

  17. Health status as evaluated by Quality of Life questionnaires (KCCQ)

    The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. This instrument was developed and validated by John Spertus. John is Director of Cardiovascular Education and Outcomes Research at the Mid America Heart Institute, and he is also a Professor of Medicine at the University of Missouri - Kansas City. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. For brevity, only the performance characteristics of the overall summary score are presented in this discussion.

    Time frame: at 30 days

  18. Health status as evaluated by Quality of Life questionnaires (EQ-5D-5L)

    EQ-5D-5L: Measures 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that can be converted to utilities using an algorithm. Utilities range from 0 to 1, with 1 representing perfect health, and 0 corresponding to the worst imaginable health state

    Time frame: at 30 days

  19. Cognitive function assessed by the MMSE

    It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment.

    Time frame: at one year

  20. The rate of new onset atrial fibrillation

    Time frame: at one year

  21. Endpoints of minimally invasive aortic valve replacement (MICS AVR) vs TAVR

    Time frame: at 30 days and one year

07

Study locations

37 of 37 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2031, 71 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 71 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Apr 11, 2025
StartActual
Jun 1, 2025
Primary completionEst.
May 31, 2031
CompletionEst.
May 31, 2040
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06924151
Lead sponsor
Osaka University
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Jun 1, 2025
Primary completion
May 31, 2031 (estimated)
Completion
May 31, 2040 (estimated)
Last update
Sep 4, 2026

Study contacts

Koichi Maeda, M.D.
Contact
k-maeda@surg1.med.osaka-u.ac.jp
+81 -6-6879-3154
Shigeru Miyagawa, M.D.
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion